Are we there yet? Bevacizumab therapy for retinopathy of prematurity.

Archives of disease in childhood. Fetal and neonatal edition

Volumn 98, Issue 2, 2013, Pages

  Darlow, Brian A ^a   Ells, Anna L ^b   Gilbert, Clare E ^b   Gole, Glen A ^b   Quinn, Graham E ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

DRUG ANTAGONISM; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGY; PREMATURITY; RETROLENTAL FIBROPLASIA; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTRAVITREAL INJECTIONS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875502256     PISSN: None     EISSN: 14682052     Source Type: None    
DOI: 10.1136/archdischild-2011-301148     Document Type: Review

References (0)